9月14日 - ** Scholar Rock（SRRK.O）股价在盘前交易中上涨10.1%，至61美元
** 美国食品药品监督管理局（FDA）已批准 (link) 公司药物Isembyld，作为首款肌肉靶向脊髓性肌萎缩症治疗药物。脊髓性肌萎缩症是一种会导致肌肉无力不断加重的遗传性疾病
** 此次批准适用于目前正在接受SMN2靶向疗法的成人及2岁及以上儿童；SMN2基因是控制运动神经元的基因
** 商业化上市工作正在进行中，产品将于未来几天内开始发货——SRRK
** 经纪公司Truist表示，广泛的适应症支持该药物峰值销售额达到23亿美元
** 截至上一交易日收盘，该股年内累计涨幅达26%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.